TIO/OLO

DRUG2 trials

Sponsors

GlaxoSmithKline, Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 4

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

CompletedNCT02799784

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2016-07-14End: 2017-04-27Updated: 2018-07-02

Unknown Phase

Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)

WithdrawnNCT04402515

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2021-10-28End: 2022-01-31Updated: 2021-11-05

Related Papers

Cost-Effectiveness of Umeclidinium/Vilanterol Versus Indacaterol/Glycopyrronium in Symptomatic patients with COPD in the UK

2023-09-09

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

Pulmonary Therapy2018-06-1318 citations

P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial

2017-11-15

P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial

2017-11-15

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

2017-11-0156 citations